Prolight signs GBP 2.24m development agreement with BRAINBox
Prolight Diagnostics today announces the successful completion of a 260-patient feasibility study and the subsequent signing of a development agreement with BRAINBox Solutions. The agreement generates revenues of approximately GBP 2.24 million (SEK 29 million) of which GBP 2,09 million (SEK 27 million) is to be recognized during the second half of 2026. In the feasibility […]
Prolight Diagnostics publishes quarterly report Q1, 2026
First quarter, January 1 – March 31, 2026 Net sales amounted to 0 (0). Other operating income amounted to 1,201 (1,662) thousand SEK. Operating profit (EBIT) amounted to -10,389 (10,937) thousand SEK. Profit after tax amounted to -10,389 (-10,937) thousand SEK. Earnings per share before and after dilution: -0.86 (-1.55) SEK. Cash flow from operating activities was -12,640 (-9,176) thousand SEK. […]
Prolight Diagnostics publishes year-end report 2025
Financial overview(figures in parentheses refer to the corresponding period in the previous year) Fourth quarter, October 1 – December 31, 2025 Net sales amounted to 0 (0). Other operating income amounted to 10,670 (15,317) TSEK. Operating profit (EBIT) amounted to -13,060 (1,492) TSEK Profit after tax amounted to -12,123 (2,014) TSEK. Earnings per share before […]
Prolight Diagnostics publishes quarterly report Q3, 2025
Financial overviewThird quarter, July 1 – September 30, 2025(figures in parentheses refer to the corresponding period in the previous year) Net sales amounted to 0 (0). Other operating income amounted to 577 (3,730) TSEK. Operating profit (EBIT) amounted to -13,908 (-8,731) TSEK. Profit after tax amounted to -13,909 (-8,795) TSEK. Earnings per share before and […]
Prolight Diagnostics publishes half-year report, 2025
Financial overviewSecond quarter, April 1 – June 30, Q2 2025(Figures in parentheses refer to the corresponding period in the previous year.) Net sales amounted to 0 (0). Other operating income amounted to 946 (18) thousand SEK. Profit after tax amounted to -12,740 (-11,224) thousand SEK. Earnings per share before and after dilution: -0.02 (-0.02) SEK. […]
Prolight’s rights issue fully subscribed
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES. Prolight […]
Prolight announces preliminary outcome of the rights issue
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES. Prolight […]
Prolight announces positive data from patient blood study at St Thomas’ Hospital, London
Data from St Thomas’ Hospital have confirmed equivalence between whole blood and plasma from patients with elevated troponin levels. The study is a key stepping-stone between the successful biobank study earlier this year and the planned clinical study for product approval. “These initial results from St Thomas’ Hospital are highly encouraging and exactly what we […]
Prolight Diagnostics publishes quarterly report Q1, 2025
Financial overview First quarter, January 1 – March 31, Q1 2025 Group(figures in parentheses refer to the corresponding period in the previous year) Net sales amounted to 0 (0). Other operating income amounted to 1,662 (68) thousand SEK. Profit after tax amounted to -10,937 (-8,929) thousand SEK. Earnings per share before and after dilution: -0.02 […]
Prolight has resolved on a rights issue of shares to complete the development of the Point of Care system Psyros™ and reach commercialisation
NOT FOR RELEASE, DISTRIBUTION OR PUBLICATION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SWITZERLAND, SINGAPORE, SOUTH AFRICA, SOUTH KOREA OR ANY OTHER JURISDICTION WHERE THE RELEASE, DISTRIBUTION OR PUBLICATION OF THIS PRESS RELEASE WOULD BE UNLAWFUL OR REQUIRE ADDITIONAL REGISTRATION OR OTHER MEASURES. The […]